Posted by Michael Wonder on 20 Jun 2023
Legacy Healthcare announces EMA validation of marketing authorisation application for coacillium for the treatment of moderate and severe alopecia areata in children and adolescents
19 June 2023 - Legacy Healthcare today announced that its marketing authorisation application to the EMA's CHMP for Coacillium for the treatment of moderate and severe alopecia areata in children and adolescents has been validated and is now under CHMP review.
The marketing authorisation application submission is based on data from the RAAINBOW trial, a randomised, double-blind, placebo controlled Phase 2/3 clinical trial.
